A significant challenge in the post-genomic era is how to prioritize differentially expressed and uncharacterized novel genes found in hepatocellular carcinoma (HCC) microarray profiling. One such category is cell cycle regulated genes that have only evolved in higher organisms but not in lower eukaryotic cells. Characterization of these genes may reveal some novel human cancer-specific abnormalities. A novel transcript, FLJ10540 was identified. FLJ10540 is overexpressed in HCC as examined by quantitative reverse transcription-polymerase chain reaction and immunohistochemistry. The patients with higher FLJ10540 expression had a poor survival than those with lower FLJ10540 expression. Functional characterization indicates that FLJ10540 displays a number of characteristics associated with an oncogene, including anchorageindependent growth, enhanced cell growth at low serum levels and induction of tumorigenesis in nude mice. FLJ10540-elicited cell transformation is mediated by activation of the phosphatidylinositol 3 0 -kinase (PI3K)/ AKT pathway. Moreover, FLJ10540 forms a complex with PI3K and can activate PI3K activity, which provides a mechanistic basis for FLJ10540-mediated oncogenesis. Together, using a combination of bioinformatics searches and empirical data, we have identified a novel oncogene, FLJ10540, which is conserved only in higher organisms. The finding raises the possibility that FLJ10540 is a potential new therapeutic target for HCC treatment.
Introduction
Hepatocellular carcinoma (HCC) is one of the most frequent malignant diseases. The development of HCC is associated with multistep processes that involve genetic alternation, such as overexpression of oncogenes. In the post-genomic era, advances in tools and technologies have provided an excellent opportunity to shed light on the disease markers and cellular pathways involved in hepatocarcinogenesis. The challenge is how to decipher the role of new genes from the logjam of unsorted information; this is problematic because there is a lack of a standard platform that integrates the various diverse data formats.
Many aberrantly expressed genes in tumor cells are involved in the regulation of the cell division cycle because some of them participate in growth and development of cancer cells. As the basic cell cycle regulatory machinery is well conserved from yeast to human, the identification of the cell cycle regulated genes that have only evolved in higher organisms, but not in lower eukaryotic cells, may reveal some novel human cancer-specific abnormalities in cell cycle regulation. Such genes need to be considered as potential therapeutic targets. We previously set up an integrative bioinformatics protocol to analyse human liver expressed sequence tag and published HCC microarray databases (Chen et al., 2002; Tsou et al., 2003) to identify a few novel regulatory genes upregulated in HCC. We then extracted 56 cell cycle G2/M-induced genes from the HeLa cell cycle microarray data (Whitfield et al., 2002) by clustering analysis. Intersection of these two data sets revealed 22 genes and 16 of them could be classified as genes that have only evolved in higher organisms and are conserved in the Mammalian, Eutheria or Amniota parts of National Center for Biotechnology Information (NCBI) HomoloGene (Yang et al., 2005) . A novel transcript FLJ10540, which is overexpressed in HCC tumor specimens and highly expressed at G2/M of HeLa cells, was chosen for further characterization in this study.
FLJ10540 has several names, including CEP55 (Fabbro et al., 2005) and C10orf3 (Sakai et al., 2006) . CEP55 fused with green fluorescent protein-C (GFP-C) tagged is localized at centrosome throughout mitosis (Fabbro et al., 2005) . In addition, at the terminal stage of cytokinesis, CEP55 is required for the midbody structure and for the completion of cytokinesis (Zhao et al., 2006) . FLJ10540 is also overexpressed in colon cancer (Sakai et al., 2006) . Microarray profiling of breast and lung cancers (Ma et al., 2003) also shows overexpression patterns in tumor specimens; however, no further analysis of FLJ10540 in human cancers has been reported.
Phosphatidylinositol 3 0 -kinase (PI3K) is a major signaling component downstream of many growth factor receptor tyrosine kinases and regulates processes that are critical for tumorigenesis (Cantley, 2002) . It is also the major mediator of survival signals that protect cells from apoptosis. PI3K activity has been shown to increase in response to a number of hormonal and growth factor stimuli, such as hepatocyte growth factor (Okano et al., 2003) and colony-stimulating factor (Kobayashi et al., 2003) . Activation of PI3K results in the phosphorylation and activation of AKT, which controls cell proliferation (Liang and Slingerland, 2003) , survival (Hanahan and Weinberg, 2000) and cell growth (Bellacosa et al., 1998) . Moreover, AKT phosphorylation frequently occurs in human lung cancer (Chen et al., 2004) , breast cancer (Nicholson et al., 2003) and HCC (Xu et al., 2004) , and has been recognized as a risk factor for early disease recurrence and poor prognosis (Nakanishi et al., 2005) .
In this study, we show that FLJ10540 is overexpressed in HCC and that ectopic expression of FLJ10540 promotes anchorage-independent growth in soft agar, enhances cell growth in low serum media, and induces tumorigenesis in nude mice. Moreover, FLJ10540 elicits cell transformation that is mediated through the PI3K/ AKT pathway. This is evident by the fact that FLJ10540 forms complex with PI3K enhances PI3K activity and thus the AKT survival pathway, suggesting that FLJ10540 is a novel oncogene and may play an important role in hepatocarcinogenesis.
Results and discussion
Overexpression of FLJ10540 in human HCC Many oncogenes are conserved evolutionarily in terms of both structure and function from invertebrates to vertebrates. This study aimed to identify and characterize novel oncogenes that are only conserved in vertebrates, but not in invertebrates, based on the hypothesis that these novel genes may possess unique function in human cancer development. Using a bioinformatics approach to search for potentially important regulatory genes involved in growth control of human HCC, FLJ10540 was identified from public accessible microarray data sets. Based on the HomoloGene orthologues database from NCBI, putative FLJ10540 orthologues were found in Pan troglodytes, Mus musculus, Rattus norvegicus and Gallus gallus, but not in Caenorhabditis elegans, Drosophila melanogaster and Saccharomyces cerevisiae. To validate the gene expression profile data for FLJ10540, quantitative reverse-transcription polymerase chain reaction (QRT-PCR) was performed on 22 matched HCC tumor and adjacent non-tumor liver samples. Figure 1a showed that overexpression of FLJ10540 was observable in our HCC patient samples; 18 of 22 HCC tumors (82%) showed higher signal after normalization to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) for equal amount of template loading. The average expression level of FLJ10540 in HCC was fourfold higher than in adjacent non-tumor liver tissue samples as analysed by boxplot (Figure 1b) , raising the possibility that upregulation of FLJ10540 might lead to the abnormalities found in human HCC.
Expression of FLJ10540 is elevated during liver regeneration
To investigate whether the expression of FLJ10540 is related to growth control of hepatocytes, we analysed FLJ10540 expression during mouse liver regeneration by RT-PCR. BALB/c mice were subjected to partial hepatectomy and total RNA was extracted from regenerating liver tissues at times ranging from 4 h to 10 days after hepatectomy. RT-PCR analysis indicated that the FLJ10540 mRNA level was very low in the normal resting liver. There was significant induction of FLJ10540 expression detected in the regeneration liver at 48 and 72 h after partial hepatectomy (Figure 1c ).
The putative domain structure of FLJ10540 We used various computer analysis software programs, including PROSITE, SMART and PSORT to analyse the deduced amino-acid sequence of human FLJ10540. FLJ10540 cDNA encodes a protein of 464 amino acids with three coiled-coil domains, a putative peroxisomal targeting signal 2 (PTS2) at N-terminus (residues 29-37), a potential nuclear export signal (NES) (residues 377-400) and a putative structure maintenance of chromosome (SMC) domain (residues 63-433) (Figure 1d ). Moreover, there is a centrosome/midbody localization signal (residues 355-464) at C-terminus (Fabbro et al., 2005) .
FLJ10540 protein is localized at the perinuclear region, cytoplasma or nucleus in HCC To examine the function of FLJ10540, human FLJ10540 cDNA was cloned using mRNA isolated from human hepatoma cell line Huh7. Purified recombinant Histagged FLJ10540 fusion protein was used to generate rabbit polyclonal FLJ10540 antibody. The anti-FLJ10540 antibody recognized a protein band of molecular mass about 54 kDa in Huh7 cells as determined by Western blot, which agrees with the estimated molecular mass (Figure 2A ). The specificity of anti-FLJ10540 antibody in the Western blot was further confirmed by competitive inhibition experiment (Figure 2A , right). Immunohistochemistry analysis was performed to determine the FLJ10540 distribution and expression levels in 118 human liver cancer tissues and to compare these results with FLJ10540 immunoreactivity in adjacent non-tumor tissues. The adjacent non-tumor hepatic cells in most of the cases showed weak but detectable FLJ10540 staining primarily at the perinuclear membrane, cytoplasma or nucleus ( Figure 2B , a and e). In contrast, strong positive immunoreactivity for during mouse liver (mL) regeneration was detected by RT-PCR. Total RNA of regenerating mouse liver RNA was analysed by RT-PCR using mouse-specific FLJ10540 primers. b2-Microglobulin primers were used as an internal control. The numbers above the lanes are hours after partial hepatectomy. (d) FLJ10540 putative protein domain structure. FLJ10540 protein has 464 amino acids and contains a PTS2 domain, an SMC domain, three coiled-coil domains, a potential NES and a centrosome and midbody localization signal.
FLJ10540 was found at the perinuclear membrane, cytoplasma or nucleus of tumor cells ( Figure 2B , b-d and f-h). There was a significantly lower level of FLJ10540 expression in adjacent non-tumor hepatic cells from all clinical specimens examined, when these were compared with tumor cells from the same patients. Overexpression of FLJ10540 was then defined as immunoreactivity against FLJ10540 in tumor cells being greater than adjacent non-tumor hepatic cells, and was further verified by immunoblotting analysis using four pairs of human adjacent non-tumor liver tissue (N) and their tumor counterparts (T) ( Figure 2B , bottom). It was clear that the tumor tissue specimens had a higher or drastic increase in FLJ10540 expression compared with adjacent non-tumor liver tissue and this is consistent with the level of FLJ10540 protein expression as determined by immunohistochemical staining. These results showed that FLJ10540 is commonly expressed in adjacent non-tumor liver tissue at a low level but is elevated in liver cancer cells.
FLJ10540 is a poor prognostic factor for HCC patients
We then compared the FLJ10540 expression pattern with clinic-pathological parameters in 118 HCC patients as described in Materials and methods. By immunohistochemistry examination, FLJ10540 protein expression levels in HCC paraffin sections were scored according to the FLJ10540 staining intensity in tumor cells. As shown in Figure 2C , the results from Kaplan-Meier curves analysis revealed a significant difference between two groups, high FLJ10540 expression in tumor part (TXN) and low FLJ10540 expression in tumor part (ToN). The survival time for those patients, who had the higher FLJ10540 protein expression in tumor tissue than its adjacent non-tumor tissue, was significantly shorter than those who have the lower FLJ10540 protein expression in tumor tissue (Po0.032 by log-rank test). These results strongly suggest that FLJ10540 is a novel prognosis factor for HCC.
FLJ10540 overexpression promotes cell survival in soft agar, in low serum medium and induces tumor formation in nude mice As FLJ10540 is overexpressed in human HCC, we next explored whether overexpression of FLJ10540 resulted in increased transformation potential. Three different cell types were employed to evaluate this possibility. Firstly, NIH3T3 cells stably expressing hemagglutinin (HA)-tagged FLJ10540 were established. Several stable transfectants with increasing levels of FLJ10540 protein were selected ( Figure 3a , upper left) and these were examined to discover whether these stable cells were able to grow in the soft agar plates. The results showed that FLJ10540 NIH3T3-stable transfectants could attach and grow well in soft agar; however, the vehicle controls formed very few colonies in soft agar ( Figure 3a , upper right). Quantitatively speaking, FLJ10540-NIH3T3 transfectants grew approximately 12-fold better than vehicle control. Secondly, to address whether FLJ10540 could also confer cell growth advantage in epithelia cells in soft agar, HA-tagged FLJ10540 stably transfected Madin-Darby canine kidney (MDCK) cells with different expression levels were characterized ( Figure 3a , middle left). Similarly, FLJ10540 MDCK-stable transfectants could attach in soft agar at a rate about 25-fold higher than vehicle MDCK cells ( Figure 3a , middle right). Finally, a retroviral-based Flag-tagged FLJ10540 was infected into a RK3E cell line that had previously The survival period of 94 HCC patients, who had higher FLJ10540 expression in tumor tissues, was significantly shorter than 24 HCC patients with lower FLJ10540 expression (P ¼ 0.032, the survival curves were analysed by the log-rank test). Overall survival was calculated from the time of surgery to date of death, as the event of interest, or the date of last follow-up. All statistical analysis was performed using SPSS software.
been used successfully to evaluate transformation induced by different genes and signaling pathways, such as Ras (Kim et al., 2006) , c-Myc (Foster et al., 1999) , b-catenin (Weng et al., 2002) . RK3E cells exhibit multiple features of epithelia, such as a near-normal karyotype and a low background of spontaneous foci. These characteristics have been used as an in vitro system for functional analysis of diverse carcinomaderived oncogenes in the context of a common host with epithelial characteristics (Ruppert et al., 1991; Kolligs et al., 2000) . To avoid clonal effects, mixed pools of infected RK3E cells (Figure 3a , bottom left) were used for the soft agar assay. Again, FLJ10540 expressing cells formed eightfold as many foci as the vehicle control cells (Figure 3c, bottom right) . Together, these findings support a role for FLJ10540 in acquiring an ability to show anchorage-independent growth in soft agar.
Alteration in the growth properties and an increase in the growth rate caused by oncoproteins are often observed in transformed cells. To investigate the role of FLJ10540 in cell proliferation, FLJ10540-NIH3T3 stable transfectants or vehicle control cells were seeded in 96 wells to test whether they could grow in low serum medium. The results showed that the vehicle control cells grew very poorly in serum-free medium and failed to proliferate. In addition, vehicle control cells grew slowly in a medium containing 0.5 or 1% serum during the first 24 h and had stopped growing by the next day (Figure 3b) . Conversely, FLJ10540-NIH3T3 stable transfectants proliferated at a steady rate in low-serum Knock down of endogenous FLJ10540 by siRNA suppresses Huh7 cell growth and induces G2/M arrest To explore whether FLJ10540 might affect the cell growth in HCC cells, we used a siRNA approach to inhibit expression of FLJ10540 and assayed for growth rate of Huh7 cells. Firstly, to examine if the FLJ10540 siRNAs could inhibit endogenous FLJ10540 expression in Huh7, we transfected two chemically synthesized FLJ10540 siRNAs (siFLJ10540-1 and siFLJ10540-2) and a negative control into Huh7 for 24-72 h followed by Western blot analysis using antibody against FLJ10540. The data showed a dramatic reduction in the FLJ10540 protein level with both FLJ10540 siRNAs, whereas there was no significant reduction of FLJ10540 when the negative siRNA was used (Figure 4a ). Finally, Huh7 cells were transfected with negative or FLJ10540 siRNAs for 24-72 h and the growth rate of these transfected Huh7 cells was determined at various time points by 3-[4,5]dimethylthiazol-2,5-diphenyltetrazolium bromide (MTT) assay. The proliferation rate of FLJ10540 siRNAs transfected cells was much slower than the cells transfected with negative siRNA (Figure 4b ). The data strongly support the idea that FLJ10540 plays a role in cell proliferation.
Many oncogenes not only play a critical role in cancer development but also affect cell cycle progression in mammalian cells. Therefore, two FLJ10540 siRNAs transfected cells were subjected to flow cytometry analysis. Knock down of FLJ10540 gave rise to cell cycle arrest at G2/M phase compared with negative siRNA-treated cells (Figure 4c) . The results indicated that the inhibition of endogenous FLJ10540 against proliferation of Huh7 cells correlated with G2/M phase cell cycle arrest. The data were further supported by the evidence that elevated protein expression of cyclin B1 was observed in FLJ10540 siRNAs-treated Huh7 cells compared with negative siRNA-treated cells (Figure 4d ). Taken together, the data strongly support the idea that FLJ10540 plays an important role in cell proliferation and alters cell cycle progression in the HCC cell lines tested.
The PI3K/AKT pathway is activated in FLJ10540 stably transfected cell To unravel the possible FLJ10540-mediated signaling pathway(s) involved in controlling transformation and cell proliferation, a panel of phosphorylated antibodies, which represent the activation state of the signaling pathways, was used to rapidly screen the possible involvement of four known kinase signaling pathways, extracellular signal-regulated kinase (ERK), c-Jun NH 2 -terminal kinase (JNK), p38 and AKT. Vehicle and NIH3T3-FLJ10540 stable transfectants were cultured with or without serum starvation. Cell lysates were examined by Western blotting with antibodies to the unphosphorylated/phosphorylated forms of ERK (P-202/204), JNK (P-183), p38 (P-180) and AKT (P-473). The activity of ERK was not significantly different between vehicle and FLJ10540 stable transfectants, whereas JNK and p38 were not phosphorylated with or without serum stimulation (Figure 5a, left) . In contrast, with or without serum starvation condition, AKT phosphorylation was elevated in FLJ10540 stable cells when compared with vehicle control cells in NIH3T3 (data not shown). To provide additional evidence for the participation of AKT in FLJ10540-elicited cell growth, we took three approaches. Firstly, we analysed whether the FLJ10540-elicited PI3K/AKT signaling pathway could be observed in other cell types. RK3E cells were infected with either Flag-tagged FLJ10540 or vehicle control. With or without serum starvation, elevated AKT phosphorylation was observed in FLJ10540-infected RK3E cells compared with vehicle control cells (Figure 5a, right) . Secondly, we examined whether the activation of AKT by FLJ10540 was mediated by PI3K. As shown in Figure 5a , FLJ10540-induced AKT-Ser 473 phosphorylation was completely abolished by wortmannin, a PI3K inhibitor. To test whether FLJ10540-elicited AKT activation is involved in cellular transformation, the transforming activity of FLJ10540 in RK3E cells was evaluated by soft-agar colony formation assay. The soft-agar colony formation of RK3E induced by FLJ10540 was significantly suppressed by the addition of wortmannin (Figure 5b ). Thirdly, we used two short hairpin RNAs (shRNAs) to inhibit endogenous expression of p110-a, a catalytic subunit of PI3K (Figure 5c , top panel), and assayed for the activation of AKT in FLJ10540 transfected HEK293T cells. Our data indicated that AKT activity was inhibited by two different p110-a shRNAs in FLJ10540 transfected cells (Figure 5c , middle panel), suggesting that FLJ10540-elicited cell growth is mediated by the PI3K/AKT pathway. These results suggested that overexpression of FLJ10540 might lead to AKT phosphorylation and activation in hepatic tumor cells. This was supported by the results from the immunohistochemical analysis using specific antibody against phospho-AKT
473
. In 40 FLJ10540 overexpression HCC patients examined, 39 showed a higher level of phospho-AKT 473 immunoreactivity in tumor cells compared with adjacent non-tumor hepatic cells and a representative picture is shown in Figure 5d . Taken together, these results strongly suggest that the activation of PI3K/AKT pathway plays a major role in FLJ10540-elicited cell proliferation and transformation of mammalian cells. FLJ10540 interacts with native heterodimeric p85-p110 PI3K complex and enhances the PI3K activity The observation that FLJ10540 enhances AKT phosphorylation in RK3E-FLJ10540 transfectants and this raises the possibility that FLJ10540 might act as a scaffold protein to provide access for AKT to its upstream kinase PI3K. To test this hypothesis, we examined whether FLJ10540 might form complex with either p110-a of PI3K or AKT. Flag-p110-a was cotransfected with either HA-FLJ10540 or vector control in HEK293T cells. Cell lysates were immunoprecipitated with anti-HA antibody and the precipitates were analysed by immunoblotting with anti-Flag antibody. Figure 6a , upper panel demonstrated that Flag-p110-a formed a complex with HA-FLJ10540. To confirm this, we performed a reciprocal experiment and demonstrated that HA-FLJ10540 could be detected in an anti-Flag antibody immunoprecipitated complex (Figure 6a , bottom). In contrast, FLJ10540 was not able to form a complex with AKT (Figure 6b ). To further verify the interaction between FLJ10540 and PI3K, we analysed the interaction of FLJ10540 with the endogenous p85-p110 heterodimeric complex. Lysates from HEK293T cells were immunoprecipitated with polyclonal antibodies against p110-a or monoclonal antibodies against FLJ10540. Immunoprecipitated proteins were analysed by immunoblotting with antibodies against p110-a, p85 or FLJ10540. The result showed that FLJ10540 was able to associate with the endogenous PI3K complex in mammalian cells (Figure 6c) .
Primed by the observation that FLJ10540 interacted with PI3K, we therefore tested whether FLJ10540 could enhance PI3K activity. Endogenous PI3K was immunoprecipitated from either RK3E-FLJ10540 transfectants or vehicle control cells using anti-p110-a antibody. The kinase activity associated with these immune complexes was measured using L-a-phosphatidylinositol protein and [g-32 P]ATP as substrates. The phosphorylation intensity of L-a-phosphatidylinositol has been demonstrated to be correlated with PI3K activity. The result showed that RK3E-FLJ10540 transfectants could enhance PI3K activity compared with the vehicle control (Figure 6d ). Moreover, PI3K activity in the RK3E-FLJ10540 transfectants was inhibited by LY294002. Taken together, these results support that FLJ10540 may associate with PI3K, modulate the PI3K activity, and result in cell transformation. Inhibition of the expression or association status of FLJ10540 might theoretically revert cancer cells to a more normal phenotype.
Materials and methods
Patients and tumor samples A total of 22 pairs of non-tumor and tumor tissues were collected from 1996 to 2000 at the Division of General Surgery of Kaohsiung Veterans General Hospital (VGH). No patients had previously received any treatment, for example chemotherapy, for HCC. The study protocol had the approval of the ethics committee at Kaohsiung Veterans General Hospital. All patients gave informed consents. Study samples, including tumor and normal tissues, were obtained during diagnostic biopsy, and normal tissues were derived from neighboring site outside of the tumor. Both tumor and normal tissues for subsequent studies were confirmed by pathologists. Liver specimens, which were obtained during hepatotomy for HCC, were used for immunoblotting and QRT-PCR. 
Immunohistochemical analysis and survival curves analyses
For immunohistochemistry analyses, tissue samples were obtained from the hospital archives and clinic-pathological data were obtained by retrospective chart review. Five micrometers sections were cut from the formalin-fixed and paraffin-embedded specimens. Briefly, the sections were deparaffinized in xylene and rehydrated in serial dilutions of ethanol (100, 95 and 75%) for 5 min each. Antigen retrieval was performed by autoclave treatment for 10 min in 0.01 M sodium citrate buffer (pH 6.4). Endogenous peroxide was quenched by the treatment with 3% H 2 O 2 in absolute methanol for 30 min at room temperature (RT). The section was blocked in 10% normal goat serum in Tris-buffered saline (TBS), followed by incubated overnight with anti-FLJ10540 antibody. After 13 h, the slides were incubation for 30 min at RT with biotinylated anti-rabbit immunoglobulin (Ig)G antibody with TBS containing 5% normal goat serum. Diaminobenzidine was used as a chromogen, followed by counterstained with hematoxylin. The survival of HCC patients was also analysed with respect to FLJ10540 expression by Kaplan-Meier method. The difference between the survival curves was examined using the log-rank test. Overall survival was calculated from the time of surgery to the date of death, or the date of last follow-up. All statistical analyses were performed using SPSS software (SPSS Inc., IL, Chicago, USA).
Quantitative reverse-transcription polymerase chain reaction To confirm the microarray data for FLJ10540, 22 pairs tumor and adjacent non-tumor tissues of HCC samples were used to validate the mRNA expression level of FLJ10540 by using QRT-PCR, which was performed using a Taq-Man probe as described previously (Su et al., 2006) . The expression pattern of FLJ10540 in normal human liver tissues (Clontech Laboratories, Palo Alto, CA, USA) was examined by RT-PCR. Data were represented as mean7s.d. To analyse the distribution of tumor and adjacent non-tumor parts, we performed the paired t-test between two groups for statistical analysis. A P-value of less than 0.05 was significant. GAPDH was used as an internal control for comparison and normalization of the data. Assays were performed in triplicate using Applied Biosystems Model 7700 instruments.
Cloning and expression of human FLJ10540 Two primers, 5 0 -ATGTCTTCCAGAAGTACCAAAG-3 0 and 5 0 -CTACTTTGAACAGTATTCCACATG-3 0 , were used to amplify the FLJ10540 cDNA from the Huh7, a cell line derived from HCC cDNA library. The purified PCR product was sequenced. GenBank accession number for FLJ10540 is NM_018131. The full-length FLJ10540 was subcloned into the pET30a, a His-tagged expression vector (Novagen, Madison, WI, USA). This plasmid was transformed into BL21(DE3) Escherichia coli strain. The transformated strains were cultured in lysogeny broth medium at 371C and induced with 1 mM isopropyl b-D-thiogalactopyranoside at A 600 ¼ 0.8 for 3-4 h. The cells were resuspended in 5 ml phosphate-buffered saline (PBS) buffer and sonicated. The supernatant was mixed with 1 ml nickel-resin (Qiagen, Hilden, Germany) for overnight at 41C. After centrifugation, the resin was washed extensively with washing buffer (20 mM imidazole, 0.3 M NaCl, 50 mM Tris-HCl, pH 7.9). The purified proteins were eluted with elution buffer (1 M imidazole, 0.5 M NaCl, 20 mM Tris-HCl, pH 7.9). For preparation of FLJ10540 antibody, 2 mg of purified His-tagged FLJ10540 recombinant protein were mixed with Freunds adjuvant and injected into rabbits to raise polyclonal antibody. FLJ10540 monoclonal antibody was purchased from Abnova (Taipei, Taiwan).
Cell culture, transient transfection, establishment of stable clones and liver regeneration All cell culture related reagents were purchased from Gibco-BRL (Grand Island, NY, USA) MDCK (clone 3B5), RK3E and NIH3T3 cells were grown in Dulbecco's modified Eagle's medium containing 10% heat-inactivated fetal bovine serum (FBS) or bovine serum (BS), 100 U/ml penicillin and streptomycin (Gibco-BRL). Transient transfection of HA-tagged FLJ10540 to MDCK, HeLa and Huh7 was performed with Lipofectamine (Gibco-BRL) according to the manufacturer's instructions, whereas RK3E cells were infected with retrovirus Flag-tagged FLJ10540. MDCK or NIH3T3 cells stably expressing FLJ10540 were selected with 800 mg/ml G418 (Calbiochem Novabiochem, San Diego, CA, USA). Individual clone was picked up and analysed for exogenous FLJ10540 expression by Western blotting. Each selected stable clones was lysed with extraction buffer (20 mM piperazine-N,N 0 -bisethane sulfonic acid (PIPES), pH 7.2, 100 mM NaCl, 1 mM ethylenediaminetetraacetic acid, 0.1% 3-[(3-cholamido propyl)-dimethylammonio]-2-hydroxy-1-propanesulfonic acid, 10% sucrose, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluorid and 1 mM Na 3 VO 4 ,) as described previously (Hsu et al., 2004) . Two double-stranded synthetic RNA oligomers (Ambion, Austin, TX, USA) (5 0 -GGGAGAAATTGCACACTTA-3 0 and 5 0 -GGACTTTTAGCAAAGATCT-3 0 ), deduced from human FLJ10540, and one Silencer negative control no. 1 siRNA (Ambion) were used for siRNA experiments. Two pCDNA3.1/U6-based p110-a shRNA plasmids (5 0 -GAGCA TGCCAATTGGTCTG-3 0 and 5 0 -GTGTTACCCAAGAA GCAGA-3 0 ) were also employed in this study. Experiments involved in the regeneration of liver tissue were carried out in BALB/c mice. After the surgery, the animals were allowed to recover for various time points ranging from 4 h to 10 days. Animals were killed and liver samples were immediately frozen in liquid nitrogen and subjected to further analysis as described earlier .
Flow cytometry
Huh7 cells transfected with two FLJ10540 siRNAs and negative control were trypsinized, and washed three times with cold PBS and were then fixed with 70% ethanol at 41C overnight. After RNase digestion for 30 min at 371C, propidium iodide (PI) was added in a final concentration of 50 mg/ml, and a flow cytometric analysis was performed on a FACS Calibur (Becton Dickinson (San Jose, CA, USA) FACStar Plus flow cytometer).
Preparation of retroviral stock and infection
Retroviral vector-derived plasmid (1 mg) introduced into 10 6 DF-1 by FuGENE 6 was described previously (Fu et al., 2005) . Viral supernatant produced from these cells was harvested. For viral infection, actively dividing RK3E/tv-a-expressing cells or control cells were seeded. The next day, cells grown in fresh growth medium were mixed with viral supernatant to a total volume of 2.5 ml for 60 mm-plate and incubated at 371C in 5% CO 2 incubator for 1 h. Afterwards, fresh growth medium was then added to the cell/virus mixtures.
Preparation of cell extracts, immunoprecipitation and Western blot analysis
Cell-free lysates were prepared as described previously (Hsu et al., 2004) . Briefly, cells were harvested, washed with PBS, and lysed in extraction buffer. Anchorage-independent growth and MTT assay for low serum growth Anchorage-independent growth ability of various MDCK, NIH3T3 and RK3E stable clones were determined by assessing colony formation efficiency in the soft agar as described previously (Wu et al., 2005) . Briefly, 1 Â 10 4 various MDCK, RK3E and NIH3T3 stable clones were suspended in 3 ml medium with 10% FBS and BS. The suspension was then added onto a layer of 10% FBS or BS containing 0.3% Seakem-agarose (Cambrex BioScience Rockland, Rockland, ME, USA) in a 60-mm dish. After 3 weeks, the colony numbers of each clone from three independent experiments were stained with crystal violet (Sigma, St Louis, MO, USA). FLJ10540-NIH3T3 stable clones (5 Â 10 3 ) were seeded in 96-well plates with either in 0, 0.5 or 1% of BS for 1-4 days followed by MTT assay to quantify the cell growth. Data were normalized against OD 570 value on day 1 of each stable clone.
PI3-kinase (PI3K) assay PI3K assay was performed as described previously (Ueki et al., 2000) . Briefly, RK3E cell extracts were immunoprecipitated with an anti-p110a antibody. The immunoprecipitates suspended in 50 ml reaction buffer containing 0.1 mg of PI (bovine liver; Avanti Polar Lipids, Inc., Alabaster, AL, USA) per ml. The reactions were initiated by adding 5 ml of MgCl 2 -ATP mixture (200 mM MgCl 2 and 200 mM ATP) containing 5 mCi of [g-32 P]ATP to the reaction mixture and incubated the mixture at 251C for 20 min. The reactions were terminated by adding 150 ml of chloroform-methanol (1:2). The organic phase was spotted onto a silica gel plate, and developed in chloroformmethanol-28% ammonium hydroxide-water. The phosphorylated lipids were visualized by autoradiography. Data were representative results from three independent experiments.
